Acadia Pharmaceuticals’ CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand and expansion into rare disease marketing, as well as its use of AI.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it seeks to expand into the rare disease space, with AI playing a major role in its marketing strategy.
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, expansion into rare disease, and use of AI throughout commercialization and marketing.
Adams shares her insights on the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.